| Literature DB >> 36267162 |
Gaia Moretta1, Tonia Samela1, Francesca Sampogna1, Francesco Ricci1, Fabio Carlesimo1, Annarita Panebianco1, Angelo Massimiliano D'Erme2, Giovanni Di Lella1, Sabatino Pallotta1, Elena Dellambra1, Damiano Abeni1, Luca Fania1.
Abstract
Actinic keratosis (AK) is considered a precancerous lesion that can develop into invasive squamous cell carcinoma. Its prevalence is increasing, and it is estimated that it affects between 1% and 44% of the adult population worldwide. Advanced age, fair skin phototypes, and cumulative sun exposure are the main risk factors for AK. Therapies for AK consists of lesion-directed treatment (i.e., cryotherapy, curettage, electrocoagulation, and laser therapy) or field therapy [i.e., photodynamic therapy (PDT), 5-fluorouracil (5-FU), diclofenac sodium (DIC), imiquimod (IMQ), and ingenol mebutate (Ing Meb)]. The type of therapy chosen is determined by the number and location of AKs, the patient's condition, and the patient's tolerability and compliance. In this survey, we collected information from 110 Italian dermatologists about their knowledge and attitudes toward various AK therapeutic approaches. In our study, we discovered that cryotherapy and PDT are the most used treatments for AK, while surgery and laser therapy are the least commonly used. The most commonly used topical therapies are DIC and IMQ 3.75 percent cream, followed by IMQ 5 percent cream, Ing Meb, and 5-FU. The correct treatment for AK can be difficult to choose, but adherence to therapy is critical for good results. Given the high and continuing rise in the incidence of AK, dermatologists' knowledge of various therapeutic approaches is critical. ©Copyright: the Author(s).Entities:
Keywords: actinic keratosis; dermatology; non-melanoma; skin tumor; therapy
Year: 2022 PMID: 36267162 PMCID: PMC9577376 DOI: 10.4081/dr.2022.9392
Source DB: PubMed Journal: Dermatol Reports ISSN: 2036-7392